Cargando…
Efficacy of repurposed antiviral drugs: Lessons from COVID-19
The clinical, social, and economic impacts of the coronavirus disease 2019 (COVID-19) pandemic, originated by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), have motivated a massive search and investment to find treatments for this new disease. Repurposing drugs has been an appealing...
Autor principal: | Martinez, Miguel Angel |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Ltd.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8857759/ https://www.ncbi.nlm.nih.gov/pubmed/35192924 http://dx.doi.org/10.1016/j.drudis.2022.02.012 |
Ejemplares similares
-
Integrating heterogeneous data to facilitate COVID-19 drug repurposing
por: Prieto Santamaría, Lucía, et al.
Publicado: (2022) -
Repurposing drugs as COVID-19 therapies: A toxicity evaluation
por: Ngan, Deborah K., et al.
Publicado: (2022) -
Drug repurposing against SARS-CoV-2 using computational approaches
por: Kumar, Sumit, et al.
Publicado: (2022) -
The current status of COVID-19 vaccines. A scoping review
por: Rueda-Fernández, Manuel, et al.
Publicado: (2022) -
Drug combination therapy for emerging viral diseases
por: Shyr, Zeenat A., et al.
Publicado: (2021)